Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge.
Novo Nordisk (NYSE:NVO) has received FDA approval for oral Wegovy, the first oral GLP-1 obesity treatment in the U.S.
The company has begun the U.S. launch of oral Wegovy, aiming to broaden access to obesity treatment beyond injectable options.
Novo Nordisk is highlighting longevity and aesthetics as future focus areas, building on research suggesting semaglutide may protect organs and reduce biological aging.
Novo Nordisk enters this new phase with oral Wegovy at a time when NYSE:NVO is priced around $43.96, after a period where the stock is down 16.1% year to date and down 44.0% over the past year. The longer term picture is mixed, with the stock down 42.8% over three years but up 14.5% over five years. This performance provides important context as investors consider the potential impact of this FDA approval and product launch.
For investors watching the obesity and diabetes space, oral Wegovy and the shift toward longevity and aesthetics could gradually reshape how Novo Nordisk is viewed, particularly as competition with Eli Lilly intensifies. Key questions now include how quickly oral adoption builds, how broad the health benefits of semaglutide prove to be, and how these developments influence investor expectations around NYSE:NVO over time.
Wall Street’s queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab’s valuation page.
NYSE:NVO Earnings & Revenue Growth as at Jun 2026
We’ve flagged 3 risks for Novo Nordisk. See which could impact your investment.
The FDA approval and U.S. launch of oral Wegovy gives Novo Nordisk a new way to reach obesity patients who are reluctant to use injections, which can expand the addressable market rather than simply shifting existing users between formats. With more than 3,000,000 prescriptions written within just over five months, the pill is already showing that there is a large pool of patients who prefer an oral GLP-1 option. That scale matters as the company faces tougher competition from Eli Lilly and, to a lesser extent, Pfizer in weight management drugs. The early traction of oral Wegovy also supports Novo Nordisk’s push to reposition semaglutide as a broader cardiometabolic and longevity platform, not only a weight loss drug. If future data on organ protection and biological aging translate into new indications in areas such as cardiovascular risk, liver health, or aesthetics, the revenue base could become less dependent on obesity alone. For now, investors are weighing this new growth channel and long-term optionality against weaker Wegovy momentum in some forecasts, pharmacy benefit manager decisions that currently favor Eli Lilly, and a 2026 outlook that includes expected pressure on sales and operating profit.
The Risks and Rewards Investors Should Consider
⚠️ Analysts point to competitive pressure from Eli Lilly and others, as some pharmacy benefit managers are currently favoring rival GLP-1 obesity treatments over Wegovy.
⚠️ Novo Nordisk’s 2026 outlook includes projected declines in adjusted sales and operating profit, which could limit how much benefit investors see from new products if pricing or reimbursement tighten further.
🎁 The FDA approval and rapid uptake of oral Wegovy, with more than 3,000,000 U.S. prescriptions in just over five months, show strong patient demand for an oral obesity GLP-1 option.
🎁 Management’s longevity and aesthetics focus, supported by research on semaglutide’s potential organ protection and biological aging effects, opens possible new indication areas beyond obesity and diabetes.
What To Watch Going Forward
From here, keep an eye on oral Wegovy prescription trends and insurer coverage decisions, especially how large pharmacy benefit managers position oral GLP-1 drugs from Novo Nordisk versus Eli Lilly and other competitors. Watch for updates on semaglutide studies that test organ protection and longevity effects, since positive data in cardiovascular disease, liver conditions, or appearance-related indications could reshape long-term revenue mix. It is also worth tracking any revisions to sales and profit guidance as oral adoption, pricing, and competition evolve, because those signals show how much of this new growth path is flowing through to the financials.
To ensure you’re always in the loop on how the latest news impacts the investment narrative for Novo Nordisk, head to the community page for Novo Nordisk to never miss an update on the top community narratives.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NVO.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com